Biomedical Engineering Reference
In-Depth Information
49. Malden LT, Novak U, Kaye AH, Burgess AW. (1988) Selective
amplification of the cytoplasmic domain of the epidermal
growth factor receptor gene in glioblastoma multiforme. Can-
cer Res . 48, 2711-2714.
50. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR,
Vogelstein B. (1987) Increased expression of the epidermal
growth factor receptor gene in malignant gliomas is invariably
associated with gene amplification. Proc. Natl. Acad. Sci. USA
84, 6899-6903.
51. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner
MH, Bigner DD, et al. (1988) Amplification and expression of
the epidermal growth factor receptor gene in human glioma
xenografts. Cancer Res. 48, 2231-2238.
52. Draoui M, Siegall CB, FitzGerald D, Pastan I, Moody TW.
(1994) TGF alpha-PE40 inhibits non-small cell lung cancer
growth. Life Sci. 54, 445-453.
53. Mesri EA, Kreitman RJ, Fu YM, Epstein SE, Pastan I. (1993)
Heparin-binding transforming growth factor alpha-Pseudom-
onas exotoxin A. A heparin sulfate-modulated recombinant
toxin cytotoxic to cancer cells and proliferating smooth muscle
cells. J. Biol. Chem. 268, 4853-4862.
54. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS,
Friedman AH, et al. (2003) Progress report of a Phase I study of
the intracerebral microinfusion of a recombinant chimeric
protein composed of transforming growth factor (TGF)-alpha
and a mutated form of the Pseudomonas exotoxin termed PE-
38 (TP-38) for the treatment of malignant brain tumors. J.
Neurooncol. 65, 27-35.
55. Weber, F. Preliminary results of a Phase II study of TP-38
immunotoxin delivered via convection-enhanced delivery to
patients with recurrent glioblastoma multiforme: report of the
TP-38 study group. Ann. Meeting German Soc. Neurosurg.,
http://www.egms.de/static/en/meetings/dgnc2005/
05dgnc0094.shtml, last accessed on Oct. 28th, 2012.
56. Debinski W, Pastan I. (1994) An immunotoxin with increased
activity and homogeneity produced by reducing the number of
lysine residues in recombinant Pseudomonas exotoxin. Bio-
conjug. Chem. 5, 40-46.
57. Debinski W, Obiri NI, Pastan, I, Puri RK. (1995) A novel
chimeric protein composed of interleukin 13 and Pseudomonas
exotoxin is highly cytotoxic to human carcinoma cells express-
ing receptors for interleukin 13 and interleukin 4. J. Biol.
Chem. 270, 16775-16780.
58. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP,
et al. (1996) Targeting of interleukin-13 receptor on human renal
cell carcinoma cells by a recombinant chimeric protein com-
posed of interleukin-13 and a truncated form of Pseudomonas
exotoxin A (PE38QQR). Blood 8 7, 4 33 3- 43 39 .
59. Joshi BH, Kawakami K, Leland P, Puri RK. (2002) Heteroge-
neity in interleukin-13 receptor expression and subunit struc-
ture in squamous cell carcinoma of head and neck: differential
sensitivity to chimeric fusion proteins comprised of interleu-
kin-13 and a mutated form of Pseudomonas exotoxin. Clin.
Cancer Res. 8, 1948-1956.
60. Kawakami K, Takeshita F, Puri RK. (2001) Identification of
distinct roles for a dileucine and a tyrosine internalization
motif in the interleukin (IL)-13 binding component IL-13
receptor alpha 2 chain. J. Biol. Chem. 276, 25114-25120.
61. Souweidane MM, Occhiogrosso G, Mark EB, Edgar MA.
(2004) Interstitial infusion of IL13-PE38QQR in the rat brain
stem. J. Neurooncol. 76, 287-293.
62. Weingart J, Strauss LC, Grossman SA. (2002) Phase I/II study:
intratumoral infusion of IL13-PE38QQR cytotoxin for recur-
rent supratentorial malignant glioma. Neuro-oncology 4, 379.
63. Kunwar S. (2003) Convection enhanced delivery of IL13-
PE38QQR for treatment of recurrent malignant glioma: pre-
sentation of interim findings from ongoing Phase 1 studies.
Acta Neurochir. Suppl. 88, 105-111.
64. Kunwar S, Prados M, Chang S, Berger MS, Lang FF,
Piepmeier JM, et al. (2003) Peritumoral convection-enhanced
delivery of IL13-PE38QQR in patients with recurrent malig-
nant glioma—Phase I interim results. Neuro-oncology 5, 4.
65. Chang SM. (2003) Neuroradiographic changes following con-
vection-enhanced delivery (CED) of the conjugated toxin
IL13-PE38QQR following resection of recurrent malignant
glioma. Neuro-oncology 5, 4.
66. Prados MD, Lang FF, Stauss LC, Fleming CK, Aldape K,
Kunwar S, et al. Intratumoral and intracerebral microinfusion
of IL13-PE38QQR cytotoxin: Phase I/II study of pre- and post-
resection infusions in recurrent resectable maliganant glioma.
Proc. Am. Soc. Clin. Oncol. 21, 2087.
67. Ram Z, Barnett G, Vogelbaum M, Constantini S, Lillehei K,
Sherman J, et al. (2003) Pre-operative infusion of IL13-
PE38QQR cytotoxin by convection-enhanced delivery
(CED) in recurrent malignant glioma: a Phase I/II study.
Proc. Am. Soc. Clin. Oncol. 22, 403.
68. http://clinicaltrials.gov, study identifier NCT00076986, s. also
www.precisetrial.com. Last accessed on Oct. 28th, 2012.
69. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J,
Barnett G, et al. (2010) Phase III randomized trial of CED of
IL13-PE38QQR vs. Gliadel wafers for recurrent glioblastoma.
Neuro-oncol. 12, 871-881.
70. Johnson VG, Wilson D, Greenfield L, Youle RJ. (1988) The
role of the diphtheria toxin receptor in cytosol translocation. J.
Biol. Chem. 263, 1295-1300.
71. Laird W, Groman N. (1976) Isolation and characterization of
tox mutants of corynebacteriophage beta. J. Virol. 19, 220-
227.
72. Greenfield L, Johnson VG, Youle RJ. (1987) Mutations in
diphtheria toxin separate binding from entry and amplify
immunotoxin selectivity. Science 238, 536-539.
73. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. (1990)
Transferrin receptor in normal and neoplastic brain tissue:
implications for brain tumor immunotherapy. J. Neurosurg. 72,
941-945.
74. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY.
(1983) Transferrin receptors in human tissues: their distribution
and possible clinical relevance. J. Clin. Pathol. 36, 539-545.
75. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC,
Mason DY. (1984) Transferrin receptor on endothelium of
brain capillaries. Nature 312, 162-163.
Search WWH ::
Custom Search